September 25, 2025
Our work on glycan-dependent T cell recruiters (GlyTRs) has been published in Cell. In this study, we introduce a new class of pan-cancer immunotherapies with “velcro-like” binding to distinguish cancer from normal cells preferentially. Targeting tumor-associated carbohydrate antigens (TACAs), GlyTRs circumvent tumor-imposed immune suppression and promote potent T cell–mediated cytotoxicity against multiple types of cancer. This study identifies a new and promising approach to safe and broadly effective cancer immunotherapy.
Read the full article here.
Find the UCI Health Press Release here.
